Holen Sie sich die Stockscreener-App
128.63
0.69%
-0.90
Handel nachbörslich:
128.63
Schlusskurs vom Vortag:
$129.53
Offen:
$129.75
24-Stunden-Volumen:
165.30K
Relative Volume:
0.54
Marktkapitalisierung:
$1.84B
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-41.72M
KGV:
-34.70
EPS:
-3.7071
Netto-Cashflow:
$-25.01M
1W Leistung:
+4.43%
1M Leistung:
+5.38%
6M Leistung:
+68.56%
1J Leistung:
+437.53%
1-Tages-Spanne:
$125.61
$133.33
1-Wochen-Bereich:
$120.34
$134.01
52-Wochen-Spanne:
$20.20
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
128.63 | 1.85B | 1.30M | -41.72M | -25.01M | -3.7071 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Mizuho | Outperform |
| 2025-12-05 | Eingeleitet | BTIG Research | Buy |
| 2025-12-04 | Eingeleitet | Craig Hallum | Buy |
| 2025-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella reports 2025 results, advances QTORIN drug pipeline - MSN
Palvella Appoints Kent Taylor as Senior Vice President of Sales - MyChesCo
Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Key Information - Minichart
Palvella Therapeutics appoints John Doux to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics appoints John Doux, M.D., to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors - Bitget
Palvella Therapeutics appoints John Doux, M.D., to board of directors - Investing.com
Palvella Therapeutics Adds Independent Dermatology Expert to Board - TipRanks
Palvella Therapeutics Appoints Dr. John D. Doux to Board of Directors to Advance Rare Disease Initiatives - Quiver Quantitative
Form 8-KCurrent report - ADVFN
Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN
Volatility Watch: How does Palvella Therapeutics Inc compare to its peersEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Palvella appoints McDonough as SVP of market access, patient services - MSN
PVLA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Singapore
Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline - MyChesCo
Palvella Publishes Review on Lymphatic Malformations in Medical Journal - MyChesCo
Palvella Therapeutics Appoints Kent Taylor as Senior Vice President of Sales - citybiz
Palvella Showcases QTORIN Platform Momentum and Commercial Readiness - TipRanks
Palvella Therapeutics Appoints Kent Taylor as Senior Vice President of Sales to Drive QTORIN™ Launch for Rare Skin Disease - Quiver Quantitative
Palvella posts corporate presentation highlighting positive Phase 3 SELVA data and NDA plans - TradingView — Track All Markets
Palvella (NASDAQ: PVLA) shows pivotal rare-disease data and $274M cash runway - Stock Titan
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales - GlobeNewswire
European Patent Office grants Palvella patent for QTORIN rapamycin - MSN
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - MSN
Breakout Move: What makes Palvella Therapeutics Inc stock attractive today2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Palvella Appoints McDonough as SVP of Market Access, Patient Services - MyChesCo
Can Palvella Therapeutics Inc lead its sector in growthPortfolio Update Summary & Safe Entry Zone Identification - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rare disease breakthrough? Palvella reports strong phase 2 results - MSN
HC Wainwright Brokers Decrease Earnings Estimates for PVLA - MarketBeat
Lifesci Capital Brokers Decrease Earnings Estimates for PVLA - MarketBeat
What is HC Wainwright's Estimate for PVLA Q1 Earnings? - marketbeat.com
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
Palvella’s Phase III Success And Fast Track Status Test Current Valuation - Yahoo Finance
Mizuho reiterates Palvella Therapeutics stock rating on pipeline By Investing.com - Investing.com Canada
Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating - marketscreener.com
Oppenheimer raises Palvella Therapeutics price target on valuation By Investing.com - Investing.com India
US Stocks Recap: What makes Palvella Therapeutics Inc stock attractive todayEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus - Sahm
Chardan raises Palvella stock price target to $240 on pipeline progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00 - MarketBeat
Palvella Highlights 2025 Results and SELVA Phase 3 Progress - TipRanks
Stifel reiterates Buy rating on Palvella stock, $250 target By Investing.com - Investing.com Canada
Oppenheimer raises Palvella Therapeutics price target on valuation - investing.com
Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN Rapamycin, Prepares NDA Submission and U.S. Launch for Rare Skin Disease Therapies - Minichart
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):